Laurence Legros

9.0k total citations · 2 hit papers
126 papers, 4.1k citations indexed

About

Laurence Legros is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Laurence Legros has authored 126 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Hematology, 90 papers in Genetics and 41 papers in Rheumatology. Recurrent topics in Laurence Legros's work include Chronic Myeloid Leukemia Treatments (84 papers), Chronic Lymphocytic Leukemia Research (65 papers) and Eosinophilic Disorders and Syndromes (41 papers). Laurence Legros is often cited by papers focused on Chronic Myeloid Leukemia Treatments (84 papers), Chronic Lymphocytic Leukemia Research (65 papers) and Eosinophilic Disorders and Syndromes (41 papers). Laurence Legros collaborates with scholars based in France, United States and Canada. Laurence Legros's co-authors include Delphine Réa, François‐Xavier Mahon, François Guilhot, Joëlle Guilhot, Gabriel Étienne, Françoise Huguet, Franck E. Nicolini, Aude Charbonnier, Bruno Varet and Josy Reiffers and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Laurence Legros

117 papers receiving 4.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

2010 1.0k citations François‐Xavier Mahon, Delphine Réa et al. profile →
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

2016 315 citations Gabriel Étienne, Joëlle Guilhot et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laurence Legros France	30	3.6k	2.7k	1.5k	723	681	126	4.1k
Susanne Saußele Germany	30	3.0k 0.8×	2.4k 0.9×	1.4k 0.9×	396 0.5×	579 0.9×	127	3.5k
Zbigniew Rudzki Australia	21	2.7k 0.7×	2.2k 0.8×	1.5k 1.0×	709 1.0×	586 0.9×	101	3.8k
Franck E. Nicolini France	19	2.7k 0.7×	2.1k 0.8×	1.2k 0.8×	400 0.6×	501 0.7×	56	3.0k
Elisabetta Abruzzese Italy	27	2.5k 0.7×	1.8k 0.6×	1.1k 0.7×	399 0.6×	538 0.8×	150	3.2k
Marilina Amabile Italy	28	2.5k 0.7×	1.6k 0.6×	1.1k 0.7×	522 0.7×	423 0.6×	80	2.9k
Nicoletta Testoni Italy	35	3.7k 1.0×	1.9k 0.7×	1.0k 0.7×	1.5k 2.1×	744 1.1×	187	4.4k
H. Kantarjian United States	29	2.4k 0.7×	2.1k 0.8×	776 0.5×	995 1.4×	637 0.9×	120	3.9k
Mary Beth Rios United States	53	6.3k 1.7×	5.0k 1.8×	3.5k 2.3×	839 1.2×	872 1.3×	129	7.4k
Barbara Waßmann Germany	23	2.3k 0.6×	1.1k 0.4×	925 0.6×	374 0.5×	534 0.8×	48	2.9k
Jianqin Shan United States	45	6.2k 1.7×	3.8k 1.4×	2.2k 1.4×	1.7k 2.3×	1.1k 1.5×	79	7.4k

Countries citing papers authored by Laurence Legros

Since Specialization

Citations

This map shows the geographic impact of Laurence Legros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurence Legros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurence Legros more than expected).

Fields of papers citing papers by Laurence Legros

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurence Legros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurence Legros. The network helps show where Laurence Legros may publish in the future.

Co-authorship network of co-authors of Laurence Legros

This figure shows the co-authorship network connecting the top 25 collaborators of Laurence Legros. A scholar is included among the top collaborators of Laurence Legros based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurence Legros. Laurence Legros is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rochet, Nathalie, Marielle Nebout, Agnès Guerci, et al.. (2023). Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia. Cancers. 15(3). 995–995. 3 indexed citations

Legros, Laurence, Catherine Guettier, Emma Goldschmidt, et al.. (2023). Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology. 91(4). 337–344. 6 indexed citations

Sorel, Nathalie, Marie‐Laure Bonnet, Jean‐Michel Goujon, et al.. (2017). Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs). Leukemia Research. 60. 94–102. 20 indexed citations

Réa, Delphine, Shanti Amé, Aude Charbonnier, et al.. (2016). Recommandations 2015 du France Intergroupe des Leucémies Myéloïdes Chroniques pour la gestion du risque d’événements cardiovasculaires sous nilotinib au cours de la leucémie myéloïde chronique. Bulletin du Cancer. 103(2). 180–189. 6 indexed citations

Legros, Laurence, Joëlle Guilhot, Sébastien Huault, et al.. (2014). Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib. Leukemia Research. 38(6). 662–665. 10 indexed citations

Dulphy, Nicolas, Guylaine Henry, Joëlle Guilhot, et al.. (2013). Low Natural Killer (NK) Cell Counts and Functionality Are Associated With Molecular Relapse After Imatinib Discontinuation In Patients (pts) With Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) With Undetectable BCR-ABL Transcripts For At Least 2 Years: Preliminary Results From Immunostim, On Behalf Of STIM Investigators. Blood. 122(21). 856–856. 24 indexed citations

Delmont, Émilien, et al.. (2013). Efficacy of Autologous Peripheral Blood Stem Cell Transplantation (Auto-PBSCT) on the Neuropathic Manifestations in POEMS Syndrome (P01.147). Neurology. 80(7_supplement). 2 indexed citations

Ianotto, Jean‐Christophe, Emmanuel Gyan, Kamel Laribi, et al.. (2013). Efficacy and safety of pegylated‐interferon α‐2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. British Journal of Haematology. 162(6). 783–791. 57 indexed citations

Natarajan‐Amé, Shanti, Sophie Park, Lionel Adès, et al.. (2012). Bortezomib combined with low‐dose cytarabine in Intermediate‐2 and high risk myelodysplastic syndromes. A phase I / II Study by the GFM. British Journal of Haematology. 158(2). 232–237. 12 indexed citations

10.

Legros, Laurence, Nathalie Ebran, Philippe Rousselot, et al.. (2012). Imatinib Sensitizes T-cell Lymphocytes From Chronic Myeloid Leukemia Patients to FasL-induced Cell Death. Journal of Immunotherapy. 35(2). 154–158. 5 indexed citations

11.

Réa, Delphine, Gabriel Étienne, Franck E. Nicolini, et al.. (2012). First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia. 26(10). 2254–2259. 30 indexed citations

12.

Avet‐Loiseau, Hervé, Florent Malard, L. Campion, et al.. (2010). Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?. Blood. 117(6). 2009–2011. 92 indexed citations

13.

Lippert, Éric, Julien Mozziconacci, Carine Gervais, et al.. (2010). Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy. Haematologica. 95(9). 1604–1607. 24 indexed citations

14.

Kelaïdi, Charikleia, Aspasia Stamatoullas, Odile Beyne‐Rauzy, et al.. (2009). Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. Haematologica. 95(6). 892–899. 13 indexed citations

15.

Adès, Lionel, Simone Boehrer, Thomas Prébet, et al.. (2008). Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood. 113(17). 3947–3952. 107 indexed citations

16.

Rousselot, Philippe, Françoise Huguet, Delphine Réa, et al.. (2006). Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 109(1). 58–60. 387 indexed citations

17.

Mannone, Lionel, Claude Gardin, Jérôme Bernard, et al.. (2006). High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. British Journal of Haematology. 133(5). 513–519. 72 indexed citations

18.

Jourdan, Éric, Françoise Rigal‐Huguet, Gérald Marit, et al.. (2005). Oneversustwo high‐dose cytarabine‐based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission. British Journal of Haematology. 129(3). 403–410. 11 indexed citations

19.

Bories, Dominique, Agnès Devergie, M Gardembas-Pain, et al.. (2003). Stratégies thérapeutiques et recommandations pour la prise en charge des patients atteints de leucémie myéloïde chronique. Hématologie. 9(6). 497–512. 2 indexed citations

20.

Legros, Laurence & Sophie Raynaud. (2002). MDS1/EVI-1, un membre de la famille des gènes codant pour des protéines à domaine PR impliqués dans la régulation de la tumorigénicité. Hématologie. 8(2). 121–128. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact